Clinical

Dataset Information

0

Phase 1 study of CS-7017 in combination with FOLFIRI


ABSTRACT: Intervention name : CS-7017 INN of the intervention : efatutazone Dosage And administration of the intervention : CS-7017(0.25-0.50 mg) administered orally twice a day Control intervention name : null Primary outcome(s): Safety and Pharmacokinetics -To evaluate the safety profile according to CTCAE -To evaluate the pharmacokinetics according to the protocol Study Design: Open Label Phase 1 Study

DISEASE(S): Metastatic Crc Who Failed First-line Therapy

PROVIDER: 2610363 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| 100185 | ecrin-mdr-crc
| 2610657 | ecrin-mdr-crc
| PRJNA777368 | ENA
| PRJNA188498 | ENA
| PRJNA66287 | ENA
2015-09-14 | GSE70797 | GEO
2007-09-10 | GSE8939 | GEO
| PRJNA698674 | ENA
| 2096559 | ecrin-mdr-crc
2019-02-01 | GSE125963 | GEO